Organogenesis Holdings Inc. reported a significant decline in net product revenue to $45.5 million for the quarter ended September 30, 2026, compared to $150.5 million in the prior year. The company experienced a net loss of $29.6 million for the quarter and $179.1 million for the nine-month period, driven by lower sales and a $30.1 million income tax expense related to the valuation of deferred tax assets.
Organogenesis Holdings Inc. reported third quarter 2026 financial results, showing a significant 70% year-over-year revenue decline to $45.5 million. The company posted a net loss of $29.6 million as it navigates what management described as a 'market reset' in the advanced wound care sector. Despite the year-over-year drop, management noted sequential revenue growth and broad-based market share gains across its portfolio.
Term
3 months
“We continue to strengthen our position as a leader in regenerative medicine as customers choose a partner and products they trust. Third quarter revenue increased sequentially, and our market share gains are broad-based across our portfolio. We are defining a sustainable future for advanced wound care as we emerge from the market reset a stronger company anchored by evidence-based living cell products that we believe will be the cornerstone of the market going forward.”
Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board